Literature DB >> 15266096

Biology and therapeutic advances for pediatric osteosarcoma.

Neyssa Marina1, Mark Gebhardt, Lisa Teot, Richard Gorlick.   

Abstract

Osteosarcoma is the most common malignant bone tumor in children and adolescents. Survival for these patients was poor with the use of surgery and/or radiotherapy. The introduction of multi-agent chemotherapy dramatically improved the outcome for these patients and the majority of modern series report 3-year disease-free survival of 60%-70%. This paper describes current strategies for treating patients with osteosarcoma as well as review of the clinical features, radiologic and diagnostic work-up, and pathology. The authors review the state of the art management for patients with osteosarcoma in North America and Europe including the use of limb-salvage procedures and reconstruction as well as discuss the etiologic and biologic factors associated with tumor development. Therapy-related sequelae and future directions in the biology and therapy for these patients are also discussed. Copyright AlphaMed Press

Entities:  

Mesh:

Year:  2004        PMID: 15266096     DOI: 10.1634/theoncologist.9-4-422

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  255 in total

1.  Skeletal imaging effects of pamidronate therapy in osteosarcoma patients.

Authors:  Anita P Price; Sara J Abramson; Sinchun Hwang; Alexander Chou; Roger Bartolotta; Paul Meyers; Douglas S Katz
Journal:  Pediatr Radiol       Date:  2010-10-30

2.  Lack of association between bcl-2 expression and prognosis of osteosarcoma: a meta-analysis.

Authors:  Tao Fu; Chengyan Xia; Zonghuan Li; Hua Wu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.

Authors:  Edwin Choy; Francis Hornicek; Laura MacConaill; David Harmon; Zeeshan Tariq; Levi Garraway; Zhenfeng Duan
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

4.  Involvement of MMP-2 in adriamycin resistance dependent on ERK1/2 signal pathway in human osteosarcoma MG-63 cells.

Authors:  Ye Ren; Fengjing Guo; Anmin Chen; Rui Deng; Jiang Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

5.  Design, synthesis and biological evaluation of ezrin inhibitors targeting metastatic osteosarcoma.

Authors:  Mikell Paige; George Kosturko; Güllay Bulut; Matthew Miessau; Said Rahim; Jeffrey A Toretsky; Milton L Brown; Aykut Üren
Journal:  Bioorg Med Chem       Date:  2013-11-14       Impact factor: 3.641

6.  p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade.

Authors:  Yong Ding; Yucai Wang; Jun Chen; Yunsheng Hu; Zhuo Cao; Pengcheng Ren; Yong Zhang
Journal:  Tumour Biol       Date:  2013-12-11

7.  Prospective study of neuropathic pain after definitive surgery for extremity osteosarcoma in a pediatric population.

Authors:  Doralina L Anghelescu; Brenda D Steen; Huiyun Wu; Jianrong Wu; Najat C Daw; Bhaskar N Rao; Michael D Neel; Fariba Navid
Journal:  Pediatr Blood Cancer       Date:  2016-08-30       Impact factor: 3.167

8.  Primary osteosarcoma of the clavicle and the perils of bone biopsy.

Authors:  William J Cundy; Christopher Carter; Deepak Dhatrak; Mark Clayer
Journal:  BMJ Case Rep       Date:  2015-04-24

9.  A new rat model of bone cancer pain produced by rat breast cancer cells implantation of the shaft of femur at the third trochanter level.

Authors:  Qi Gui; Chengcheng Xu; Liang Zhuang; Shu Xia; Yu Chen; Ping Peng; Shiying Yu
Journal:  Cancer Biol Ther       Date:  2012-12-19       Impact factor: 4.742

Review 10.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.